Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NAARDEN, THE NETHERLANDS AND MIAMI, MAY 11, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

NEWAMSTERDAM PHARMA TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES IN MAY

 DECISIONS ON REGULATORY APPROVAL FROM EMA, UK, AND SWITZERLAND FOR OBICETRAPIB AND OBICETRAPIB/EZETIMIBE FIXED - DOSE COMBINATION EXPECTED IN 2H26, AND BASED ON THE OUTCOMES, WITH POTENTIAL LAUNCHES BY MENARINI IN 4Q26 IN GERMANY AND THE UK   PREVAIL INTERIM ANALYSIS PLANNED FOR 4Q2026 WITH RESULT EXPECTED IN 1Q2027   COMPLETED ENROLLMENT IN REMBRANDT; TOPLINE DATA FROM RUBENS PHASE 3 EXPECTED BY YEAR-END 2026   PRESENTED NEW ANALYSES OF PHASE 3 BROOKLYN AND BROADWAY STUDIES AT THE AMERICAN COLLEGE OF CARDIOLOGY ANNUAL SCIENTIFIC SESSION (ACC) AND SIMULTANEOUSLY PUBLISHED IN THE AMERICAN JOURNAL OF PREVENTATIVE CARDIOLOGY  $707.3 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AT MARCH 31, 2026   MANAGEMENT TO HOST PREVAIL UPDATE CALL TODAY AT 8:00 AM ET  NAARDEN, THE NETHERLANDS AND MIAMI, MAY 07, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026 AND PROVIDED A CORPORATE UPDATE.

NEWAMSTERDAM PHARMA PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER FINANCIAL RESULTS

NAARDEN, THE NETHERLANDS AND MIAMI, MAY 01, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF NEWAMSTERDAM'S BOARD OF DIRECTORS APPROVED THE GRANT OF INDUCEMENT SHARE OPTIONS COVERING AN AGGREGATE OF 50,400 OF NEWAMSTERDAM'S ORDINARY SHARES TO FIVE NON-EXECUTIVE NEW HIRES. THE SHARE OPTIONS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE EMPLOYEES' ACCEPTANCE OF EMPLOYMENT WITH NEWAMSTERDAM PURSUANT TO THE NEWAMSTERDAM PHARMA COMPANY N.V. 2024 INDUCEMENT PLAN (THE 2024 INDUCEMENT PLAN) AND IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

NEWAMSTERDAM PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

NAARDEN, THE NETHERLANDS AND MIAMI, APRIL 08, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT IAN SOMAIYA, CHIEF FINANCIAL OFFICER, AND MATTHEW PHILIPPE, EXECUTIVE VICE PRESIDENT, HEAD OF INVESTOR RELATIONS, WILL PARTICIPATE IN A VIRTUAL FIRESIDE CHAT AT THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE ON MONDAY, APRIL 13, 2026 AT 11:45 A.M.

NEWAMSTERDAM PHARMA TO PRESENT AT THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

NAARDEN, THE NETHERLANDS AND MIAMI, APRIL 02, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF NEWAMSTERDAM'S BOARD OF DIRECTORS APPROVED THE GRANT OF INDUCEMENT SHARE OPTIONS COVERING AN AGGREGATE OF 15,000 OF NEWAMSTERDAM'S ORDINARY SHARES TO TWO NON-EXECUTIVE NEW HIRES. THE SHARE OPTIONS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE EMPLOYEES ACCEPTANCE OF EMPLOYMENT WITH NEWAMSTERDAM PURSUANT TO THE NEWAMSTERDAM PHARMA COMPANY N.V. 2024 INDUCEMENT PLAN (THE 2024 INDUCEMENT PLAN) AND IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

NAARDEN, THE NETHERLANDS AND MIAMI, MARCH 23, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT IT WILL PRESENT DATA HIGHLIGHTING THE POTENTIAL FOR OBICETRAPIB AS A NOVEL, ORAL, LOW-DOSE THERAPY FOR HYPERCHOLESTEROLEMIA, AT THE AT THE AMERICAN COLLEGE OF CARDIOLOGY ANNUAL SCIENTIFIC SESSION (ACC.26), TAKING PLACE ON MARCH 28-30 IN NEW ORLEANS, LOUISIANA.

NEWAMSTERDAM PHARMA ANNOUNCES THREE PRESENTATIONS AT THE 2026 AMERICAN COLLEGE OF CARDIOLOGY ANNUAL SCIENTIFIC SESSION

NAARDEN, THE NETHERLANDS AND MIAMI, MARCH 06, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF NEWAMSTERDAM'S BOARD OF DIRECTORS APPROVED THE GRANT OF INDUCEMENT SHARE OPTIONS COVERING AN AGGREGATE OF 10,000 OF NEWAMSTERDAM'S ORDINARY SHARES TO TWO NON-EXECUTIVE NEW HIRES. THE SHARE OPTIONS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE EMPLOYEES' ACCEPTANCE OF EMPLOYMENT WITH NEWAMSTERDAM PURSUANT TO THE NEWAMSTERDAM PHARMA COMPANY N.V. 2024 INDUCEMENT PLAN (THE 2024 INDUCEMENT PLAN) AND IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

NAARDEN, THE NETHERLANDS AND MIAMI, FEB. 25, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

NEWAMSTERDAM PHARMA TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES IN MARCH

-- APPROVAL DECISIONS FROM EMA, UK AND SWITZERLAND REGULATORS FOR OBICETRAPIB AND OBICETRAPIB/EZETIMIBE FIXED DOSE COMBINATION EXPECTED IN 2H26 -- -- PHASE 3 PREVAIL CVOT BLINDED EVENT RATE TRACKING IN LINE WITH OBSERVED EVENT RATE IN BROADWAY--    -- TOPLINE DATA FROM RUBENS PHASE 3 TRIAL IN PATIENTS WITH TYPE 2 DIABETES AND METABOLIC SYNDROME EXPECTED BY YEAR-END 2026 -- -- $728.9 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AT DECEMBER 31, 2025 -- NAARDEN, THE NETHERLANDS AND MIAMI, FEB. 18, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2025 AND PROVIDED A CORPORATE UPDATE.

NEWAMSTERDAM PHARMA REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

NAARDEN, THE NETHERLANDS AND MIAMI, FEB. 06, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF NEWAMSTERDAM'S BOARD OF DIRECTORS APPROVED THE GRANT OF INDUCEMENT SHARE OPTIONS COVERING AN AGGREGATE OF 217,000 OF NEWAMSTERDAM'S ORDINARY SHARES TO FOUR (4) NON-EXECUTIVE NEW HIRES. THE SHARE OPTIONS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE EMPLOYEES' ACCEPTANCE OF EMPLOYMENT WITH NEWAMSTERDAM PURSUANT TO THE NEWAMSTERDAM PHARMA COMPANY N.V. 2024 INDUCEMENT PLAN (THE 2024 INDUCEMENT PLAN) AND IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

NAARDEN, THE NETHERLANDS AND MIAMI, FEB. 04, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT IAN SOMAIYA, CHIEF FINANCIAL OFFICER, AND MATTHEW PHILIPPE, EXECUTIVE VICE PRESIDENT, HEAD OF INVESTOR RELATIONS, WILL PARTICIPATE IN A VIRTUAL FIRESIDE CHAT AT THE GUGGENHEIM EMERGING OUTLOOK: BIOTECH SUMMIT ON WEDNESDAY, FEBRUARY 11, 2026 AT 8:30 A.M. ET.

NewAmsterdam Pharma Company N.V.

NAMS

Price

Financial Reports

No items found.

Press Releases

NewAmsterdam Pharma Company N.V.

NAMS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NAMS